【摘要】 2025年全球妇科肿瘤领域聚焦于卵巢癌、子宫内膜癌和宫颈癌三大瘤种，以诊疗精准分层、耐药攻坚、技术革新为核心。卵巢癌方面，TRUST研究证实对于体能良好患者PCS方案更优，ICON8B研究验证了剂量密集化疗的生存获益，KEYNOTE-B96研究及抗体药物偶联物（antibody-drug conjugate,ADC）类药物、瑞拉可兰（relacorilant）联合方案为铂类药物耐药患者带来新选择。宫颈癌方面，中国原创PHENIX研究确立前哨淋巴结活检（sentinel lymph node biopsy,SLNB）精准手术范式，SHR-1210-Ⅲ-329研究推动“去化疗”方案，innovaTV 301中国数据使ADC类药物进入二线治疗。子宫内膜癌方面，依托分子分型实现精准治疗，AtTEnd、SIENDO等研究为不同亚型患者提供个体化治疗方案。2025年中国原创研究在多领域取得突破，期待未来强化国产创新药研发和国际协作。更多还原

【Abstract】 In 2025, the global gynecologic oncology field focused on three major cancer types: ovarian, endometrial, and cervical cancer, with core themes revolving around precise treatment stratification, tackling drug resistance, and technological innovation. For ovarian cancer, the TRUST study confirmed the superiority of the PCS regimen for patients with good performance status. The ICON8B study validated the overall survival benefit of dose-dense chemotherapy. For platinum-resistant patients, the KEYNOTEB96 study, along with antibody-drug conjugate(ADC) and regimens combining relacorilant, offered new options. For cervical cancer, in China, the original PHENIX study established a paradigm for precise surgery with sentinel lymph node biopsy(SLNB). The SHR-1210-Ⅲ-329 study promoted "chemotherapy-free" regimens. Data from the innovaTV 301 study in China positioned ADC drugs as a second-line treatment option. For endometrial cancer: treatment precision was achieved through molecular classification, with studies like AtTEnd and SIENDO providing individualized strategies for patients across different subtypes. In 2025, original Chinese research achieved breakthroughs across multiple areas, reinforcing the expectation for strengthening domestic innovative drug development and international collaboration in the future.更多还原